| http://purl.uniprot.org/citations/28507002 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/28507002 | http://www.w3.org/2000/01/rdf-schema#comment | "Exploratory clinical trials using therapeutic anti-HER3 antibodies strongly suggest that neuregulin (NRG1; HER3 ligand) expression at tumor sites is a predictive biomarker of anti-HER3 antibody efficacy in cancer. We hypothesized that in NRG1-expressing tumors, where the ligand is present before antibody treatment, anti-HER3 antibodies that do not compete with NRG1 for receptor binding have a higher receptor-neutralizing action than antibodies competing with the ligand for binding to HER3. Using time-resolved-fluorescence energy transfer (TR-FRET), we demonstrated that in the presence of recombinant NRG1, binding of 9F7-F11 (a nonligand-competing anti-HER3 antibody) to HER3 is increased, whereas that of ligand-competing anti-HER3 antibodies (H4B-121, U3-1287, Ab#6, Mab205.10.2, and MOR09825) is decreased. Moreover, 9F7-F11 showed higher efficacy than antibodies that compete with the ligand for binding to HER3. Specifically, 9F7-F11 inhibition of cell proliferation and of HER3/AKT/ERK1/2 phosphorylation as well as 9F7-F11-dependent cell-mediated cytotoxicity were higher in cancer cells preincubated with recombinant NRG1 compared with cells directly exposed to the anti-HER3 antibody. This translated in vivo into enhanced growth inhibition of NRG1-expressing BxPC3 pancreatic, A549 lung, and HCC-1806 breast cell tumor xenografts in mice treated with 9F7-F11 compared with H4B-121. Conversely, both antibodies had similar antitumor effect in NRG1-negative HPAC pancreatic carcinoma cells. In conclusion, the allosteric modulator 9F7-F11 shows increased anticancer effectiveness in the presence of NRG1 and thus represents a novel treatment strategy for NRG1-addicted tumors. Mol Cancer Ther; 16(7); 1312-23. ©2017 AACR."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.org/dc/terms/identifier | "doi:10.1158/1535-7163.mct-16-0886"xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Prost J.F."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Chardes T."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Mathis G."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Mondon P."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Bazin H."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Lazrek Y."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Poul M.A."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Pelegrin A."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Le Clorennec C."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Ogier C."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Garambois V."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Larbouret C."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Barret J.M."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/author | "Dubreuil O."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/date | "2017"xsd:gYear |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/name | "Mol Cancer Ther"xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/pages | "1312-1323"xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/title | "Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3."xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://purl.uniprot.org/core/volume | "16"xsd:string |
| http://purl.uniprot.org/citations/28507002 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/28507002 |
| http://purl.uniprot.org/citations/28507002 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/28507002 |
| http://purl.uniprot.org/uniprot/#_A0A024QY88-mappedCitation-28507002 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/28507002 |